Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Unusual Machines Q1 2026 Earnings Call - Record Revenue Growth and Strategic Battery Acquisition Fuel Supply Chain Dominance
Unusual Machines delivered a blistering Q1 2026, posting $8.1 million in revenue, a 296% year-over-year surge, and $10.3 million in net profit. The company is capitalizing on a severe supply-demand im...
- Revenue surged 296% year-over-year to $8.1 million in Q1 2026, marking the eighth consecutive quarter of record revenue growth.
- Net profit reached $10.3 million for the quarter, with core operations remaining profitable even after excluding $9.5 million in unrealized investment gains.
- The company secured $150 million in a confidential public offering at $17 per share, bringing total working capital to approximately $320 million.
- +7 more takeaways
Shimmick Q1 2026 Earnings Call - Highest Book-to-Bill Ratio Signals Backlog Surge and Margin Expansion
Shimmick delivered a sharp turnaround in the first quarter of 2026, posting consolidated revenue of $88 million and a 12% consolidated gross margin, driven by an 89% year-over-year improvement in core...
- Consolidated revenue of $88 million, with Shimmick core projects generating $88 million and non-core projects dropping to $200,000 from $29 million year-over-year.
- Core Shimmick project gross margin expanded 89% year-over-year to 11%, reflecting improved project selection and execution discipline.
- Total gross margin reached 12%, up from 4% in Q1 2025, driven by the elimination of non-core margin drag and better mix on core work.
- +7 more takeaways
Cibus Q1 2026 Earnings Call - Accelerating Commercial Execution Amid Regulatory Tailwinds
Cibus is pivoting from foundational R&D to aggressive commercial execution in Q1 2026, driven by a $37 million capital raise and a clear shift toward revenue-generating milestones. The company deliver...
- Raised $37 million in gross proceeds via two public offerings in Q1 2026, extending cash runway into Q1 2027.
- Delivered gene-edited rice materials to Interoc in May, a critical step toward the planned 2027 Latin American commercial launch.
- U.S. rice launch delayed to 2029 due to herbicide registration timelines for clethodim; management stresses LATAM is the primary near-term revenue engine.
- +7 more takeaways
Clipper Realty Q1 2026 Earnings Call - Residential Rents Hit Record Highs as Office Asset Struggles
Clipper Realty reported strong residential leasing momentum in Q1 2026, with new free market rents rising over 7% and overall occupancy holding near 99%. The company’s stabilized residential portfolio...
- Residential free market rents rose over 7% on new leases and 5% on renewals, with overall occupancy at 99% across stabilized properties.
- New free market lease rates are at all-time highs, with specific assets like Tribeca House and Clover House averaging $90–$95 per foot.
- AFFO fell to $2.3 million from $8 million year-over-year, driven by a $5.8 million hit from the 250 Livingston Street lease termination and initial lease-up expenses at Prospect House.
- +7 more takeaways
Eton Pharmaceuticals Q1 2026 Earnings Call - Record Sales Surge and Raised Guidance Driven by DESMODA and HEMANGEOL Launches
Eton Pharmaceuticals delivered a record first quarter with product revenue jumping 73% year-over-year to $24.3 million, fueled by strong growth across its existing rare disease portfolio and the initi...
- Product revenue surged 73% year-over-year to $24.3 million in Q1 2026, driven by growth across INCRELEX, ALKINDI SPRINKLE, Galzin, and carglumic acid, plus early sales from DESMODA and HEMANGEOL.
- Full-year revenue guidance was raised to exceed $120 million, up from $110 million, reflecting strong base business performance and early momentum from new product launches.
- Adjusted EBITDA reached $5.7 million, representing a 24% margin, with management reaffirming its target of a 50% adjusted EBITDA margin by 2028.
- +7 more takeaways
Legacy Education Inc. Q3 FY2026 Earnings Call - Record Revenue Growth and Disciplinary Scaling in Healthcare Education
Legacy Education reported a record third quarter for fiscal 2026, with revenue jumping 15% to $21.4 million and adjusted EBITDA rising 12.6% to $4.4 million. The company is capitalizing on structural ...
- Revenue surged 15% year-over-year to $21.4 million in Q3 FY2026, driven by expanded program offerings and improved student retention.
- Adjusted EBITDA climbed 12.6% to $4.4 million, with the adjusted EBITDA margin holding steady at 20.6%.
- Educational services expenses as a percentage of revenue improved by 270 basis points to 51.7%, highlighting significant operating leverage in the academic delivery model.
- +7 more takeaways
Alpha Cognition Inc. Q1 2026 Earnings Call - ZUNVEYL Revenue Surges 40% as Prescriber Adoption Accelerates
Alpha Cognition delivered a strong Q1 2026, with ZUNVEYL revenues jumping 40% quarter-over-quarter to $3.5 million. The company is executing a deliberate commercial expansion, adding a 60-person sales...
- ZUNVEYL revenues reached $3.5 million in Q1 2026, marking a 40% sequential increase and accelerating demand trends into April.
- Prescriber adoption is gaining momentum, with HCP writers growing 23% quarter-over-quarter to 1,060, positioning the company on track for its 2026 goal of approximately 2,000 prescribers.
- Nursing home penetration expanded by 25%, reaching 914 facilities with an 81% repeat order rate, indicating durable adoption and sustained utilization.
- +7 more takeaways
RenovoRx Q1 2026 Earnings Call - Revenue Doubles as Commercial Execution Outpaces Clinical Timeline
RenovoRx delivered its strongest quarter to date, with Q1 2026 revenue doubling to $563,000, driven by a rapid expansion of active commercial centers from eight to sixteen. The company is executing a ...
- Q1 2026 revenue reached $563,000, a 136% increase from Q4 2025 and the company's highest quarterly revenue to date.
- Active commercial cancer centers doubled from eight at year-end 2025 to sixteen as of May 2026, with 32 additional centers in the pipeline.
- RenovoRx reiterated its full-year 2026 revenue guidance of $3 million to $4 million, with Q2 revenue expected to exceed Q1.
- +7 more takeaways
Genasys Inc. Q2 2026 Earnings Call - Profitability Returns as Debt Extension Buys Time for Puerto Rico Receivables
Genasys delivered its first GAAP net income profitability in fiscal Q2 2026, driven by a 124% year-over-year revenue surge to $15.5 million. The quarter was anchored by the Puerto Rico Dam Emergency W...
- Genasys achieved GAAP net income profitability for the first time in fiscal Q2 2026, reporting $600,000 in net income versus a $6.1 million loss in the prior year period.
- Revenue surged 124% year-over-year to $15.5 million, with hardware revenue jumping 180% and software revenue growing 6% to $2.4 million.
- Gross margins reached a record 63.3%, driven by favorable product mix, the recognition of Puerto Rico project revenue, and increased software sales.
- +7 more takeaways
Bridgeline Digital Q2 FY2026 Earnings Call - Record Sales and AI-Driven Pipeline Surge
Bridgeline Digital delivered its strongest quarter ever, tripling Q1 sales and securing 19 new logos with $2.8 million in total contract value and $1.2 million in annual recurring revenue. The average...
- Record-breaking new logo acquisition: Bridgeline signed 19 new customers this quarter, the highest in company history, closing $2.8 million in TCV and $1.2 million in ARR.
- Surge in average contract value: The average new SaaS customer license price leaped to $44,000 in ARR, up from $30,000 last quarter and $21,000 a year ago, fueled by larger enterprise deals and AI add-ons.
- Strong expansion revenue: Existing customers purchased an average of $28,000 in ARR for add-on products, highlighting the stickiness and upsell potential of the HawkSearch suite.
- +7 more takeaways